Logo
    Search

    Shankar Siva on radiotherapy for primary renal cell carcinoma

    enNovember 28, 2022

    About this Episode

    Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

    Read the full article:
    5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Recent Episodes from The Lancet Oncology in conversation with

    Maria Kyrgiou on innovations in gynaecological cancers and global disparities

    Maria Kyrgiou on innovations in gynaecological cancers and global disparities

    In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

    Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

    Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

    Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

    Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

    Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

    Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Neerja Bhatla on a new quadrivalent HPV vaccine

    Neerja Bhatla on a new quadrivalent HPV vaccine

    Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

    Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

    Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

    Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

    Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.

    Read the full Policy Review:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Wanda Cui on measuring ovarian toxicity

    Wanda Cui on measuring ovarian toxicity

    Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    Ticiana Leal on Tumour Treating Fields

    Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA

    Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA

    Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv